ProQR Therapeutics N.V. PRQR
Biotechnology: Pharmaceutical Preparations · IPO 2014 · data as of November 13, 2026
ProQR Therapeutics N.V. (PRQR) is a healthcare company listed in the US with a market value of about $199M. In the twelve months to June 30, 2026 it had revenue of $20M and net income of -$46M, a net margin of -228.9%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -53%.
About ProQR Therapeutics
ProQR Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2014. Revenue went from $2M in 2021 to $19M in 2025, growth of about 87.5% a year. It was profitable in 0 of the last 10 years in our data.
Score: 0.8 / 5
Checks passed
- 3-year revenue growth above 10% a year
- Profit margin improving
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $20M | $19M | $20M | $7M | $4M | $2M | — | — | — | — | — |
| Net income | -$46M | -$50M | -$29M | -$31M | -$69M | -$69M | -$57M | -$63M | -$42M | -$52M | -$41M |
| Free cash flow | -$55M | -$63M | -$39M | $22M | -$74M | -$30M | -$59M | -$50M | -$33M | -$42M | -$39M |
| EPS (diluted) | $-0.44 | $-0.35 | $-0.20 | $-0.22 | $-0.49 | $-0.49 | $-0.40 | $-0.45 | $-0.30 | $-0.37 | $-0.29 |
| Net margin | -228.9% | -265.2% | -146.9% | -431.7% | -1792.5% | -4549.8% | — | — | — | — | — |
| ROIC | — | -63.3% | -32.5% | -69.5% | -69.7% | -28.6% | -45.0% | -42.3% | -28.0% | -68.7% | -53.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does ProQR Therapeutics pay a dividend?
Not currently.
Is ProQR Therapeutics a good stock to buy?
We do not give buy or sell advice. ProQR Therapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.